Human cancer cell lines that have acquired resistance to the PARP inhbitor ABT-888 have also been previously shown to have reduced PARP1 levels, although these cells also acquired resistance to ionising radiation [19], which our Parp1 mutant cells did not (Figure 5B). This evidence concerns the gene PARP1 and cancer.